End-of-day quote
Shanghai S.E.
06:00:00 2024-05-08 pm EDT
5-day change
1st Jan Change
4.22
CNY
+0.72%
+2.68%
-26.09%
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2020
April 29, 2021 at 12:28 pm EDT
Shanghai Fudan Forward S&T Co. Ltd. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was CNY 940.327 million compared to CNY 1,399.901 million a year ago. Operating loss was CNY 22.922 million compared to operating Income of CNY 54.578 million a year ago. Net loss was CNY 55.832 million compared to net income of CNY 55.511 million a year ago. Basic loss per share from continuing operations was CNY 0.082 compared to basic earnings per share from continuing operations of CNY 0.081 a year ago.
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 29
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
Apr. 29
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-27
CI
Fudan Forward S&T to Auction Office Property For At Least 31 Million Yuan
23-10-12
MT
Fudan Forward S&T Chairman Retires
23-09-29
MT
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-30
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-28
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
23-04-28
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-28
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
22-08-26
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
22-04-29
CI
Tranche Update on Shanghai Fudan Forward S&T Co., Ltd's Equity Buyback Plan announced on June 30, 2021.
22-03-31
CI
Shanghai Fudan Forward S&T Co., Ltd's Equity Buyback announced on June 30, 2021, has expired with 5,365,068 shares, representing 0.78% for CNY 35.01 million.
22-03-29
CI
Tranche Update on Shanghai Fudan Forward S&T Co., Ltd's Equity Buyback Plan announced on June 30, 2021.
22-01-04
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021
21-10-29
CI
Tranche Update on Shanghai Fudan Forward S&T Co., Ltd's Equity Buyback Plan announced on June 30, 2021.
21-10-08
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2021
21-08-27
CI
Shanghai Fudan Forward S&T Co., Ltd commences an Equity Buyback Plan for CNY 70 million worth of its shares, under the authorization approved on April 8, 2021.
21-06-29
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021
21-04-29
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2020
21-04-29
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2020
20-10-30
CI
Shanghai Fengxian Investment Co., Ltd. completed the acquisition of 10% stake in Shanghai Fudan Forward Pharmaceutical Co., Ltd. from Shanghai Fudan Forward S&T Co., Ltd
20-09-22
CI
Shanghai Fengxian Investment Co., Ltd., completed the acquisition of 18.74% stake in Shanghai Fudan Forward S&T Co., Ltd from Fudan University, Endowment Arm.
20-09-03
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2020
20-08-21
CI
Shanghai Fudan Forward S&T Co., Ltd Announces Tax Included Final Cash Dividend for the Full Year of 2019, Payable on August 03, 2020
20-07-22
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
SHANGHAI FUDAN FORWARD S&T CO., LTD is a China-based company, principally engaged in the manufacture and distribution of pharmaceuticals. The Company's pharmaceuticals include digestive system drugs, nervous system drugs, antineoplastic drugs, circulatory drugs, immune function medications and others. The Company is also engaged in the provision of financial insurance software products. It distributes its products within domestic markets and to overseas markets.
More about the company
1st Jan change
Capi.
-26.09% 397M +19.83% 42.97B +24.52% 22.49B +17.11% 14.93B +7.75% 13.14B +42.93% 11.67B -8.84% 6.86B -0.05% 6.79B -8.87% 5.73B +13.13% 5.54B
Generic Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1